酪氨酸蛋白激酶受体c-Met及靶点药物研究进展  

Research Progress on the Receptor Tyrosine Protein Kinase and Targeted Drugs

作　　者：苏传铃[1,2] 王斌[1] 罗红宇[1] 曲有乐[1] 

机构地区：[1]浙江海洋学院食品与药学学院,浙江舟山316004 [2]佳木斯大学药学院,黑龙江佳木斯154007

出　　处：《浙江海洋学院学报（自然科学版）》2010年第3期273-278,共6页Journal of Zhejiang Ocean University(Natural Science Edition)

基　　金：浙江省自然科学基金(Y2080579;Y2090678);浙江海洋学院校级课题(21135030107;11132100409)

摘　　要：酪氨酸激酶受体c-Met在细胞的代谢、分化以及死亡细胞的信号传导过程中起着重要的作用,其与配体结合,可活化其信号通路,参与胚胎发育、组织损伤修复以及肿瘤的发生和发展。因而,以酪氨酸激酶受体c-Met为靶点的抗肿瘤药物已经成为肿瘤研究中十分活跃的领域,为抗肿瘤治疗提供了新方法。The c-Met oncogene,encoding the receptor tyrosine kinase,plays an important role in the process of cellular metabolism,differentiation and signal transduction of cell death.HGF combine c-Met can induce activation of a series of signal pathway and stimulate embryonic development,repair tissue injury and development of tumor.Thus,anticancer drugs of therapeutic target of c-Met has become very active in the cancer research field and provides a new approach for anti-tumor therapy.

关 键 词：受体酪氨酸激酶 C-MET 靶点药物 

分 类 号：S356[农业科学—作物栽培与耕作技术]